Condition: Prostate Cancer (Adenocarcinoma) · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Sponsor: Acerand Therapeutics (Hong Kong) Limited
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Sherwin Cai, MD · 86-18983021726 · sherwin.cai@acerand.com
Teresa Shi, MS · 86-13916513539 · teresa.shi@acerand.com
Always discuss trial participation with your own doctor first.
| University of California San Diego, Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Moffitt Cancer Center, Tampa | Tampa, Florida, United States | Recruiting |
| University of Maryland, Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Harvard Medical School-Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| M Health Fairview Clinics and Surgery Center | Minneapolis, Minnesota, United States | Recruiting |
| Xcancer (Urology Cancer Center) | Omaha, Nebraska, United States | Recruiting |
| Carolina Urologic Research Center | Myrtle Beach, South Carolina, United States | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06801236